Surmodics FY2025 EPS Estimate Lifted by Barrington Research

Key Points

• Barrington Research has raised its FY2025 earnings per share estimate for Surmodics to ($0.30) from a previous estimate of ($0.57), while maintaining a "Market Perform" rating on the stock.
• Surmodics reported Q2 earnings of $0.06 per share, significantly beating analyst estimates of ($0.21) and achieving revenues of $29.57 million compared to a consensus of $28.04 million.
• Institutional investors hold a dominant stake in Surmodics, owning 96.63% of the company's shares, with several hedge funds recently increasing their positions.

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Barrington Research lifted their FY2025 EPS estimates for shares of Surmodics in a report issued on Monday, August 11th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of ($0.30) for the year, up from their prior forecast of ($0.57). Barrington Research currently has a "Market Perform" rating on the stock. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.12) EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.27. The company had revenue of $29.57 million during the quarter, compared to the consensus estimate of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%.

Separately, Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research note on Wednesday, April 30th.

Surmodics Stock Performance

NASDAQ SRDX opened at $37.92 on Wednesday. The firm has a 50-day moving average of $31.61 and a 200-day moving average of $30.83. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.10 and a current ratio of 3.91. The stock has a market cap of $542.26 million, a PE ratio of -30.83 and a beta of 1.31. Surmodics has a 52-week low of $26.00 and a 52-week high of $40.38.

Institutional Trading of Surmodics

A number of hedge funds have recently modified their holdings of the stock. Millennium Management LLC raised its stake in Surmodics by 0.4% in the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company's stock worth $4,766,000 after purchasing an additional 509 shares in the last quarter. Principal Financial Group Inc. raised its stake in Surmodics by 1.8% in the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company's stock worth $1,120,000 after purchasing an additional 638 shares in the last quarter. Legal & General Group Plc raised its stake in Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after purchasing an additional 880 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Surmodics by 705.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock worth $37,000 after purchasing an additional 1,080 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Surmodics by 0.3% in the 2nd quarter. Geode Capital Management LLC now owns 336,239 shares of the company's stock worth $9,992,000 after purchasing an additional 1,128 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.